AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M

Benzinga

02 Apr

Fiscal Year 2025 Financial Guidance

For fiscal year 2025:

The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.
The Company continues to expect Med Device net sales to be flat.
The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.
The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.

Guidance Metric	Guidance Action	Current Guidance (As of Apr. 2, 2025)	Previous Guidance (Issued on Jan. 8, 2025)
Net Sales	Increased	$285 - $288 million	$282 - $288 million
Med Tech Net Sales Growth	Increased	14 - 16%	12 - 15%
Med Device Net Sales Growth	Unchanged	Flat (unchanged)	Flat
Gross Margin	Increased	53 - 54%	52 - 53%
Adjusted EBITDA	Increased	$4.0 - $5.0 million	$1.0 - $3.0 million
Adjusted EPS	Increased	($0.31) - ($0.34)	($0.34) - ($0.38)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2524463169"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524463169\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524463169?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524463169","market":"us","top_or_hot":-1,"title":"AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M","media":"Benzinga","content":"<html><body><p><strong>Fiscal Year 2025 Financial Guidance</strong></p><p>For fiscal year 2025:</p><ul><li>The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.</li><li>The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.</li><li>The Company continues to expect Med Device net sales to be flat.</li><li>The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.</li><li>The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.<br/> </li></ul><figure><table><tbody><tr><td colspan=\"1\" rowspan=\"1\"><strong>Guidance Metric</strong></td><td colspan=\"1\" rowspan=\"1\"><strong>Guidance Action</strong></td><td colspan=\"1\" rowspan=\"1\"><p><strong>Current Guidance</strong></p><p><i>(As of Apr. 2, 2025)</i></p></td><td colspan=\"1\" rowspan=\"1\"><p><strong>Previous Guidance</strong></p><p><i>(Issued on Jan. 8, 2025)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Net Sales</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">$285 - $288 million</td><td colspan=\"1\" rowspan=\"1\">$282 - $288 million</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Med Tech Net Sales Growth</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">14 - 16%</td><td colspan=\"1\" rowspan=\"1\">12 - 15%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Med Device Net Sales Growth</td><td colspan=\"1\" rowspan=\"1\">Unchanged</td><td colspan=\"1\" rowspan=\"1\">Flat (unchanged)</td><td colspan=\"1\" rowspan=\"1\">Flat</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Gross Margin</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">53 - 54%</td><td colspan=\"1\" rowspan=\"1\">52 - 53%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EBITDA</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">$4.0 - $5.0 million</td><td colspan=\"1\" rowspan=\"1\">$1.0 - $3.0 million</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EPS</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">($0.31) - ($0.34)</td><td colspan=\"1\" rowspan=\"1\">($0.34) - ($0.38)</td></tr></tbody></table></figure></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2025-04-02 18:35</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Fiscal Year 2025 Financial Guidance</strong></p><p>For fiscal year 2025:</p><ul><li>The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.</li><li>The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.</li><li>The Company continues to expect Med Device net sales to be flat.</li><li>The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.</li><li>The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024.<br/> </li></ul><figure><table><tbody><tr><td colspan=\"1\" rowspan=\"1\"><strong>Guidance Metric</strong></td><td colspan=\"1\" rowspan=\"1\"><strong>Guidance Action</strong></td><td colspan=\"1\" rowspan=\"1\"><p><strong>Current Guidance</strong></p><p><i>(As of Apr. 2, 2025)</i></p></td><td colspan=\"1\" rowspan=\"1\"><p><strong>Previous Guidance</strong></p><p><i>(Issued on Jan. 8, 2025)</i></p></td></tr><tr><td colspan=\"1\" rowspan=\"1\">Net Sales</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">$285 - $288 million</td><td colspan=\"1\" rowspan=\"1\">$282 - $288 million</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Med Tech Net Sales Growth</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">14 - 16%</td><td colspan=\"1\" rowspan=\"1\">12 - 15%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Med Device Net Sales Growth</td><td colspan=\"1\" rowspan=\"1\">Unchanged</td><td colspan=\"1\" rowspan=\"1\">Flat (unchanged)</td><td colspan=\"1\" rowspan=\"1\">Flat</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Gross Margin</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">53 - 54%</td><td colspan=\"1\" rowspan=\"1\">52 - 53%</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EBITDA</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">$4.0 - $5.0 million</td><td colspan=\"1\" rowspan=\"1\">$1.0 - $3.0 million</td></tr><tr><td colspan=\"1\" rowspan=\"1\">Adjusted EPS</td><td colspan=\"1\" rowspan=\"1\">Increased</td><td colspan=\"1\" rowspan=\"1\">($0.31) - ($0.34)</td><td colspan=\"1\" rowspan=\"1\">($0.34) - ($0.38)</td></tr></tbody></table></figure></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANGO","symbol_name":"阿吉奥动态","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/04/44602919/angiodynamics-expects-2025-net-sales-of-285m-288m-compared-to-prior-guidance-of-282m-288m-and-conse","article_id":"2524463169","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524463169","pubTimestamp":1743590135,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Fiscal Year 2025 Financial GuidanceFor fiscal year 2025:The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ANGO":"阿吉奥动态"},"translate_title":"AngioDynamics预计2025年净销售额为2.85亿至2.88亿美元，而之前的指引为2.82亿至2.88亿美元，共识为2.8491亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANGO":1},"content_text":"Fiscal Year 2025 Financial GuidanceFor fiscal year 2025:The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.The Company continues to expect Med Device net sales to be flat.The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024. Guidance MetricGuidance ActionCurrent Guidance(As of Apr. 2, 2025)Previous Guidance(Issued on Jan. 8, 2025)Net SalesIncreased$285 - $288 million$282 - $288 millionMed Tech Net Sales GrowthIncreased14 - 16%12 - 15%Med Device Net Sales GrowthUnchangedFlat (unchanged)FlatGross MarginIncreased53 - 54%52 - 53%Adjusted EBITDAIncreased$4.0 - $5.0 million$1.0 - $3.0 millionAdjusted EPSIncreased($0.31) - ($0.34)($0.34) - ($0.38)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}